Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Matsusaka S, et al. Among authors: parekh a. Clin Cancer Res. 2016 Jul 1;22(13):3218-26. doi: 10.1158/1078-0432.CCR-15-2422. Epub 2016 Feb 2. Clin Cancer Res. 2016. PMID: 26839145 Free PMC article. Clinical Trial.
Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Ning Y, et al. Among authors: parekh a. Mol Cancer Ther. 2015 Oct;14(10):2401-8. doi: 10.1158/1535-7163.MCT-15-0359. Epub 2015 Jul 30. Mol Cancer Ther. 2015. PMID: 26227487 Free PMC article.
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. Matsusaka S, et al. Among authors: parekh a. Mol Cancer Ther. 2016 Jun;15(6):1405-11. doi: 10.1158/1535-7163.MCT-15-0751. Epub 2016 Mar 16. Mol Cancer Ther. 2016. PMID: 26983880 Free PMC article.
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. Okazaki S, et al. Among authors: parekh a. Mol Cancer Ther. 2016 Jul;15(7):1740-5. doi: 10.1158/1535-7163.MCT-15-0931. Epub 2016 May 11. Mol Cancer Ther. 2016. PMID: 27196764 Free PMC article.
Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.
Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. Stremitzer S, et al. Among authors: parekh a. Mol Cancer Ther. 2016 Nov;15(11):2814-2821. doi: 10.1158/1535-7163.MCT-16-0275. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535973 Free PMC article.
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.
Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. Sunakawa Y, et al. Among authors: parekh a. Ann Oncol. 2015 Dec;26(12):2450-6. doi: 10.1093/annonc/mdv474. Epub 2015 Sep 28. Ann Oncol. 2015. PMID: 26416897 Free PMC article. Clinical Trial.
Genetic variants associated with colorectal brain metastases susceptibility and survival.
Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ. Stremitzer S, et al. Among authors: parekh a. Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22. Pharmacogenomics J. 2017. PMID: 26689941 Free PMC article.
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.
Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ. Sunakawa Y, et al. Among authors: parekh a. Pharmacogenomics J. 2017 Dec;17(6):528-534. doi: 10.1038/tpj.2016.46. Epub 2016 May 31. Pharmacogenomics J. 2017. PMID: 27241062 Free PMC article.
CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.
Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. Matsusaka S, et al. Among authors: parekh a. Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9. Pharmacogenomics J. 2017. PMID: 27503580 Free PMC article.
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ. Matsusaka S, et al. Among authors: parekh a. Pharmacogenomics J. 2018 Apr;18(2):262-269. doi: 10.1038/tpj.2017.9. Epub 2017 Apr 11. Pharmacogenomics J. 2018. PMID: 28398355 Free PMC article.
541 results